NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free VRCA Stock Alerts $5.92 +0.27 (+4.78%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.60▼$6.0150-Day Range$4.74▼$5.9952-Week Range$2.86▼$7.76Volume88,474 shsAverage Volume152,160 shsMarket Capitalization$251.13 millionP/E RatioN/ADividend YieldN/APrice Target$11.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Verrica Pharmaceuticals alerts: Email Address Verrica Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.0% Upside$11.25 Price TargetShort InterestBearish17.38% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.61Based on 5 Articles This WeekInsider TradingAcquiring Shares$892,901 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.59) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsMedical Sector111th out of 938 stocksPharmaceutical Preparations Industry41st out of 425 stocks 3.5 Analyst's Opinion Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.25, Verrica Pharmaceuticals has a forecasted upside of 90.0% from its current price of $5.92.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.38% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 22.4, which indicates bearish sentiment.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently decreased by 0.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVerrica Pharmaceuticals has received a 75.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Verrica Pharmaceuticals is -0.67. Previous Next 3.1 News and Social Media Coverage News SentimentVerrica Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for VRCA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $892,901.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.50% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.59) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 12.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBuy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.And for the first time in 2024, he’s sharing his strategy for free. About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Read More VRCA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRCA Stock News HeadlinesMarch 28, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 27, 2024 | msn.comVerrica Pharma gains as FDA lists Ycanth in Orange BookMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 26, 2024 | markets.businessinsider.comVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsMarch 26, 2024 | globenewswire.comVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 3, 2024 | msn.comVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside ChatMarch 2, 2024 | finance.yahoo.comVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 2, 2024 | finance.yahoo.comWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?March 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 1, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy RatingMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market ExpansionMarch 1, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market AcceptanceFebruary 29, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 28, 2024 | benzinga.comEarnings Outlook For Verrica PharmaceuticalsFebruary 27, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceFebruary 22, 2024 | finance.yahoo.comVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024February 22, 2024 | globenewswire.comVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024February 12, 2024 | msn.comVerrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options TradersFebruary 6, 2024 | finance.yahoo.com7 Potential Short-Squeeze Stocks Poised for Rapid GainsFebruary 5, 2024 | bizjournals.comVerrica Pharmaceuticals sues Canadian drug maker, alleging false advertising and unfair competitionFebruary 5, 2024 | msn.comVerrica sues to keep unapproved cantharidin drugs off US marketFebruary 5, 2024 | markets.businessinsider.comVerrica Pharma Files Suit Against Dormer Lab Alleging False Advertising, Unfair CompetitionFebruary 5, 2024 | seekingalpha.comVerrica sues to keep unapproved catharidin drugs off US marketFebruary 5, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair CompetitionSee More Headlines Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRCA CUSIPN/A CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$11.25 High Stock Price Target$14.00 Low Stock Price Target$8.00 Potential Upside/Downside+90.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,000,000.00 Net Margins-1,307.47% Pretax Margin-1,307.47% Return on Equity-119.46% Return on Assets-70.35% Debt Debt-to-Equity Ratio2.22 Current Ratio4.55 Quick Ratio4.49 Sales & Book Value Annual Sales$5.12 million Price / Sales49.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book12.60Miscellaneous Outstanding Shares42,420,000Free Float24,815,000Market Cap$251.13 million OptionableOptionable Beta1.87 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ted White (Age 59)President, CEO & Director Comp: $772.77kMr. Joe Bonaccorso (Age 60)Chief Commercial Officer Comp: $550.37kDr. Gary Goldenberg M.D. (Age 47)Chief Medical Officer Comp: $553.03kMr. P. Terence KohlerChief Financial OfficerMr. Christopher G. Hayes (Age 60)Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel Mr. Eugene ScavolaExecutive Vice President of Technical OperationsDr. Bradley J. Catalone MBAPh.D., Head of Drug DevelopmentMore ExecutivesKey CompetitorsAtossa TherapeuticsNASDAQ:ATOSCorMedixNASDAQ:CRMDG1 TherapeuticsNASDAQ:GTHXVanda PharmaceuticalsNASDAQ:VNDATrevi TherapeuticsNASDAQ:TRVIView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 34,243 shares on 3/11/2024Ownership: 2.973%Perceptive Advisors LLCBought 2,060,199 shares on 2/26/2024Ownership: 16.879%GSA Capital Partners LLPBought 15,332 shares on 2/16/2024Ownership: 0.092%Barclays PLCBought 25,008 shares on 2/15/2024Ownership: 0.068%Citadel Advisors LLCSold 6,700 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VRCA Stock Analysis - Frequently Asked Questions Should I buy or sell Verrica Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRCA shares. View VRCA analyst ratings or view top-rated stocks. What is Verrica Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued 1-year price objectives for Verrica Pharmaceuticals' stock. Their VRCA share price targets range from $8.00 to $14.00. On average, they predict the company's stock price to reach $11.25 in the next year. This suggests a possible upside of 90.0% from the stock's current price. View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts. How have VRCA shares performed in 2024? Verrica Pharmaceuticals' stock was trading at $7.32 at the start of the year. Since then, VRCA stock has decreased by 19.1% and is now trading at $5.92. View the best growth stocks for 2024 here. When is Verrica Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VRCA earnings forecast. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.01. The firm earned $1.99 million during the quarter, compared to analysts' expectations of $1.10 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 1,307.47%. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS). When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (16.88%), Avoro Capital Advisors LLC (9.51%), Vanguard Group Inc. (3.00%), Vanguard Group Inc. (2.97%), Northern Trust Corp (0.47%) and BML Capital Management LLC (0.43%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Joe Bonaccorso, John A Stalfort III, Paul B Manning, Perceptive Advisors Llc and Ted White. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRCA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.